12:00 AM
 | 
Dec 13, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 12/10 cls
Basilea Pharmaceutica AG (SIX:BSLN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) 4% CHF67.05
van Renterghem said the company is now fairly valued based on his target of CHF65. He believes there will be limited catalysts to drive the stock until late 2011, when Phase III data for alitretinoin to treat severe hand eczema are anticipated. The once-daily vitamin A derived 9-cis retinoic...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >